ReviewPharmacoEconomics2021
The Challenges of Measuring Informal Care Time: A Review of the Literature.
Review in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Trial
- Longitudinal Impact of Agitation and Aggression Symptoms on Societal Costs in Alzheimer's Disease: A Focus on Informal Care and Socioeconomic Disparities.International journal of geriatric psychiatry · 2026Observational
- Spillover Effects of Medical Innovations: A Universal and Scalable Approach to Measure the Societal Value of Avoided Informal Care Time.Applied health economics and health policy · 2026Article
- The economic burden of neurological disorders in Europe - COIN-Eu: Study design and analytic framework.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Economic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Practical Guidance.PharmacoEconomics · 2026Review
- Measuring, valuing, and incorporating patient and caregiver productivity costs in economic evaluations: a scoping review and environmental scan.International journal of technology assessment in health care · 2026Article
- Economic value of non-professional care in Spain. An analysis of the last decade.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- The Societal Burden of Breast Cancer in Working-Age Women in Croatia: A Multicentre Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- The economics of decision-making in dementia care and related life-limiting illness: a narrative review.Health economics review · 2026Review
- Health economic evaluation of an interdisciplinary care pathway for older patients with vertigo, dizziness and balance disorders in primary care (MobilE-PHY2) - a cluster-randomised trial.Cost effectiveness and resource allocation : C/E · 2026Article
- Introducing an Expanded Value Framework in Health Technology Assessment of Vaccines.Journal of market access & health policy · 2026Article
- Adopting a Societal Perspective in Health-Economic Evaluation: Analysis of Nine HTA Methodological Guidelines on How to Integrate Societal Costs.Journal of market access & health policy · 2026Article
- Measuring and valuing spillover effects in caregivers and families: A scoping review.PloS one · 2026Article
- An Introduction to Costing and the Types of Costs Used within Health Economic Studies.PharmacoEconomics - open · 2025Review
- Social inequalities in the use of formal and informal home care in older women: evidence from a large UK cohort study.Age and ageing · 2025Article
- Does the Informal Carer Identification Method Matter? Evidence from Self-Declaration and Time Diary Approaches.PharmacoEconomics · 2025Article
- A Perspective on Making "Invisible" Care Visible Through Time Use Data.Journal of aging & social policy · 2025Article
- Psychometric validation and cultural adaptation of the Chinese version of the CarerQol-7D instrument.Health and quality of life outcomes · 2025Article
- EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19?PharmacoEconomics · 2025Article
- Non-medical costs incurred by critically ill patients with dengue, sepsis and tetanus within a major referral hospital in Southern Vietnam: a cost of illness study.BMJ public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Economic evaluations increasingly include the value of informal care, for example, in terms of caregiver health effects or time costs. If an economic evaluation uses caregiving time costs, appropriate measurement of caregiving time is an important first step prior to its valuation. There is no comprehensive overview of the measurement challenges for caregiving time. In this literature review, we searched Medline, Embase, Econlit and Scopus to identify measurement issues and associated studies which reported informal care time that addressed them. The search identified 27 studies that addressed nine measurement issues. There is limited evidence on how to address these issues, although some have received relatively more attention, including incremental time (considered in 16 studies), time measurement method comparisons (six studies) and the inclusion of intangible tasks (four studies). Non-response (considered in only one study) and carer and recipient identification (two studies) were the most wide-reaching measurement concerns, as these determine who is identified as carers. There was no evidence on the consequences of these measurement challenges in terms of impacts on cost-effectiveness ratios and on the total cost of health conditions, which would be a crucial next step. Future research on these issues should consider a range of different settings, as informal care is highly heterogeneous. The measurement of informal care is key for its inclusion in economic evaluations but there is little consensus on how to appropriately measure this type of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.